Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions;Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables

Medicina Clinica

Volumn 129, Issue 10, 2007, Pages 361-365

  Pedrol, Enric ^a   Martín, Teodoro ^b   Del Pozo, Miguel Angel ^c   Flores, Juan ^d   Sanz, José ^e   Carton J A ^f   Jusdado, Juan José ^g   Arazo, Piedad ^h   Ribera, Esteve ⁱ   Deig, Elisabet ^a   De La Torre, J ^j   Terron A ^k   Munoz L ^l   Marquez M ^m   Pascuau, J ⁿ   Lopez M ⁿ   Lopez M A ⁿ   Arazo, P ^o   Asensi, V ^f   Echevarria S ^p   Morales, J M ^q   Rodriguez M M ^q   Del Pozo, M A ^r   Sanchez J ^s   Duenas C ^t   Locutura, J ^t   Lorenzo, J F ^t   Fuertes, A ^u   Cordero, M ^u   Rosa, C ^v   Garcia J ^w   Ferrer, L ^x   Rubio, M ^d   Curucull, J ^y   Arribas, P ^y   Javaloyas, M ^z   Knobel, H ^aa   Pedrol, E ^ab   Deig, E ^ab   Antoni, J ^ac   Sanchez C ^ad   Dalmau, D ^ad   Martinez X ^ad   Cervantes, M ^ae   Domingo, P ^af   Colomer, J ^ag   Paradineiro J C ⁱ   Orti, A ^ah   Camba, M ^ai   Flores, J ^aj   Alcacer F ^ak   Guix, J ^ak   Galindo, M J ^ak   Arnal, M ^al   Minguez C ^am   Andres J ^am   Gomez J E ^an   Rodriguez S J ^ao   Sanchez F ^ap   Pascua, F J ^ap   Camara T ^aq   Naval, G ^ar   Rodriguez R ^ar,as   Diz, J ^as   Ojea De Castro, R ^as   Lopez M J ^at   Marino A ^au   Prieto, A ^av   Losada, E ^av   Asorey, A ^aw   Castro, A ^ax   Lopez M S ^ax   Cifuentes, C ^ay   Homar, F ^ay   Martin T ^b   Fernandez M ^az   Gorgolas M ^az   Sanchez F J ^ba   Maradona, J A ^ba   Perez E ^bb   Roca, V ^bb   Menendez M A ^bc   De Los Santos, I ^bd   Sanz, J ^e,bd   Barros, C ^be   Padilla, B ^bf   Fernandez F ^bf   Berenguer, J ^bf   Garcia Lechuz J C ^bf   Gijon P ^bf   Miralles, P ^bf   Casas, E ^e   De Miguel, J ^e   Jusdado, J J ^g   Torres, R ^g   Rubio, T ^bg   more..

^a HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL SEVERO OCHOA   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j H Costa del Sol   (Spain)

^k H Jerez de la Frontera   (Spain)

^l HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^m H Virgen de la Victoria   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^o H Miguel Servet   (Spain)

^p HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^q H Universitario de Guadalajara   (Spain)

^r H Clínico Universitario de Valladolid   (Spain)

^s HOSPITAL RÍO CARRIÓN   (Spain)

^t HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^u HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^v H Virgen de la Luz   (United States)

^w Centro Penitenciario Brians   (Spain)

^x HOSPITAL DOS DE MAIG   (Spain)

^y H de Figueras   (Spain)

^z H de Viladecans   (Spain)

^aa H del Mar   (Spain)

^ab H General de Granollers   (Spain)

^ac H Germans Trias i Pujol   (Spain)

^ad HOSPITAL MÚTUA DE TERRASSA   (Spain)

^ae Hospital Parc Tauli   (Spain)

^af H Sant Pau   (Spain)

^ag H Santa Caterina   (Spain)

^ah HOSPITAL VERGE DE LA CINTA   (Spain)

^ai H Povisa   (Spain)

^aj Arnau Hospital of Vilanova   (Spain)

^ak H Clínico de Valencia   (Spain)

^al H de Vinarós   (Spain)

^am H General Castellón   (Spain)

^an H Luis Alcañiz   (Spain)

^ao H de Vinarós ^*  (Spain)

^ap Geriatric Service Hospital Ntra Sra de la Montaña Complejo Hospitalario de Cáceres   (Spain)

^aq HOSPITAL DON BENITO VILLANUEVA   (Spain)

^ar Servicio Gallego de Salud   (Spain)

^as Department of Neurology   (Spain)

^at HOSPITAL XERAL CALDE   (Spain)

^au Universidad de La Coruña   (Spain)

^av H Clínico Santiago   (Spain)

^aw H de Meixoeiro   (Spain)

^ax HOSPITAL JUAN CANALEJO   (Spain)

^ay HOSPITAL SON LLÀTZER   (Spain)

^az Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^ba HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^bb HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^bc H de la Defensa   (Spain)

^bd HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^be Univ H   (Spain)

^bf HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^bg Reina Sofía Hospital   (Spain)

more..

Author keywords

AIDS; Dose reduction; Efficacy; HIV; Security; Stavudine

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; VIRUS LOAD;

EID: 35348859649     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13110209     Document Type: Article

References (28)

1. Gallant JE, Staszewsi S, Pozniak AL, DeJesus E, Suleiman JMAH, Millar MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-years randomized trial. JAMA. 2004;292:191-201.
2. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide drug exposure. Antivir Ther. 2001;6 Suppl 3:25-44.
3. Whitcomb J, Parkin NT, Chappey C, Hellmann NS, Petropolus CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infec Dis. 2003;188:992-1000.
4. U.S. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents - Oct 10, 2006. Disponible en: http://www.aidsinfo.nih.gov/
5. Spruance S, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann Intern Med. 1997;126:355-63.
6. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hidroxyurea. AIDS. 2000;14:273-8.
7. Domingo P, Labarga P, Palacios R, Guerro MF, Terrón JA, Elías MJ, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS. 2004;18:1475-8.
8. John M, McKinnon EJ, Jarnes IR, Nollan DA, Herrmann SE, Moore CB, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. JAIDS. 2003;33:29-33.
9. Pedrol E, Ribell M, Deig E, Villà MC, Miró O, Garrabou G, et al. Tratamiento de la hiperlactatemia sintomática y de la acidosis láctica en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa análogos de los nucleósidos. Med Clin (Barc). 2005;125: 201-4.
10. Ficha técnica Zerit®.
11. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-91.
12. Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with AIDS. N Engl J Med. 1990;323:1009-14.
13. Collier AC, Bozzette S, Coombs RW, Causey DM, Schoenfeld DA, Spector SA, et al. A pilot study of lowe-dose zidovudine in HIV infection. N Engl J Med. 1990;323:1015-21.
14. Kimura S, Shinichi O, Toyoshima T, Hirabayshi Y, Kikuchi Y, Mitamura K, et al. A randomized trial of reduced doses of azidothymidine in japanese patients with HIV type 1 infection. Intern Med. 1992;31:871-6.
15. Petersen EA, Ramírez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis. 1995;171 Suppl 2:131-9.
16. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1:417-22.
17. Hanvanich M, Prasanthai V, Riengchan P, Arunyingmongkol K, Intalapaporn P, Suankratay C, et al. Reduction of d4T dosages improves lipoatrophy without virologic failure [resumen 749]. Actas de 2nd IAS Conference on HIV Pathogenetics and treatment; 2003; Paris.
18. Shalit P, Farrell P, Mcclarty M. Long-term efficacy of a protease inhibitor sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage. HIV Clin Trials. 2004;5:62-4.
19. Delpierre C, Cuzin L, Álvarez M, Khatibi S, Bonnet E, Obadia M, et al. Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-1 infected patients [resumen 9.4/2]. Actas de 9th European AIDS Conference; 2003, octubre 25-29; Varsovia.
20. Koegl C, Wolf E, Postel N, Buchberger A, Ruemmelein N, Jaegel-Guedes E, et al. Low dose stavudine: as effective as standard dose but less side effects [resumen 9.8/5]. Actas de 9th European AIDS Conference; 2003, octubre 25-29; Varsovia.
21. Urbina A, Jibilian A, Nibbe Y, Maa JF, Wang S. Long term use of low dose stavudine is effective and well tolerated [resumen TuPe2.2B31]. Actas de 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005, julio 24-27; Rio de Janeiro. Rio de Janeiro: IAS; 2005.
22. Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, et al. Evaluation of viral efficacy and safety of a reduced dose of stavudine: the Phoenix study [resumen PE7.3/19]. 10th European AIDS Conference; 2005, noviembre 17-20; Dublin.
23. Sánchez-Conde M, De Mendoza C, Jiménez-Nacher I, Barreiro P, González-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials. 2005;6:197-202.
24. Ribera E, Paradiñeiro JC, Domingo P, Sauleda S, Luque S, García-Arumí E, et al. A randomized study comparing the efficacy and tolerability of low-dose versus standard-dose stavudine in antiretroviral-naïve patients (ETOX study) [resumen TuPe2.4C10]. Actas de 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005, julio 24-27; Rio de Janeiro. Rio de Janeiro: IAS; 2005.
25. Lichtenstein KA, Armon C, Wood KC, Moorman AC, Holmberg SD, Brooks JT. Influence of host and disease factors on ART-associated co-morbidities [resumen 852]. Actas de 12th Conference on Retroviruses and Opportunistic Infections; 2005, febrero 22-25; Boston.
26. Milinkovic A, López S, Vidal S, Miró O, Fernández X, Arnaiz JA, et al. A randomized open study comparing the effect of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. Antivir Ther. En prensa 2007.
27. Haslinger BA, Arendt G. Optimal d4T-therapy in HIV-1 positive patients from a neurological point of view -lower dose, less side effects, equal effectivity? [resumen WePeB5924]. Actas de XV International AIDS Conference; 2004, julio, 11-16; Bangkok.
28. Siangphoe U, Srikaew S, Waiwaravuth C, Chariyasetphong T, Kamsaw O, Klinbua V, et al. Efficacy and safety of half dose compared to full dose d4T and AZT in combination with ddI in Thai HIV-infected patients: 96 weeks results of ACTT002/ARV065 study [resumen WePeB5952]. Actas de XV International AIDS Conference; 2004, julio, 11-16; Bangkok.